Medicare Part D and Medicare Advantage (Part C) plans with drug coverage typically cover inhalers for COPD. But you may still be responsible for a portion of the cost. If you have chronic obstructive ...

There was a notable gap in effectiveness between metered-dose and dry-powder formulations of single-inhaler triple therapy for chronic obstructive pulmonary disease (COPD), according to real-world ...

Results showed that a dry powder inhaler loaded with umeclidinium and vilanterol produced a 14% lower risk of moderate or severe COPD flare-ups, compared to a metered-dose inhaler loaded with ...

New research from UCLA Health suggests that certain inhalers used to treat chronic obstructive pulmonary disease (COPD) are ...

Some people with chronic obstructive pulmonary disease (COPD) need to use multiple inhaled medicines each day to control their symptoms. Long-acting combination inhalers that contain more than one ...

A generic fluticasone-salmeterol (Wixela Inhub) maintenance inhaler was clinically equivalent to name-brand Advair Diskus for chronic obstructive pulmonary disease (COPD), a propensity score-matched ...

Please provide your email address to receive an email when new articles are posted on . Several clinicians expressed concern about inhaler costs for those with COPD in January. AstraZeneca, Boehringer ...

Add Yahoo as a preferred source to see more of our stories on Google. Inhalers that provide fast-acting treatment for people with certain respiratory conditions are contributing to greenhouse gas ...

Please provide your email address to receive an email when new articles are posted on . The single inhaler combined budesonide, glycopyrrolate and formoterol fumarate. The risk for cardiopulmonary ...

Those receiving budesonide-glycopyrrolate-formoterol compared with fluticasone-umeclidinium-vilanterol had a higher risk for a first moderate COPD exacerbation. William B. Feldman, MD, MPH, from ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved the world’s first low-carbon version of a triple-combination inhaler for chronic obstructive pulmonary disease (COPD). The ...

Key market opportunities in the inhaler solution market include the rising demand driven by increased respiratory disorders like asthma and COPD, expanding access to medicines in low and middle-income ...